We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.02% | 65.55 | 65.55 | 66.00 | 66.14 | 65.16 | 65.43 | 7,318,161 | 01:00:00 |
From May 2021 to May 2024
By Michael Dabaie
Gilead Sciences Inc. said the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for sacituzumab govitecan as monotherapy in unresectable or metastatic triple-negative breast cancer.
Gilead said it anticipates the final European Commission decision on the marketing authorization application for sacituzumab govitecan later in 2021.
The pharma company said TNBC is the most aggressive type of breast cancer and accounts for about 15% of all breast cancers.
The positive opinion is supported by results from the Phase 3 Ascent study, where sacituzumab govitecan showed a 57% reduction in the risk of disease worsening or death and improved median progression-free survival.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 15, 2021 08:37 ET (12:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
